C83.13
BillableMantle cell lymphoma, intra-abdominal lymph nodes
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
Is C83.13 an HCC code?
Yes. C83.13 maps to Lung and Other Severe Cancers under the CMS-HCC V28 risk adjustment model (and Lymphoma and Other Cancers under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for C83.13
For C83.13 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C83.13 during that encounter — not just copy-forwarded from a problem list.
What This Code Means
C83.13 is the ICD-10-CM diagnosis code for mantle cell lymphoma, intra-abdominal lymph nodes. Mantle cell lymphoma is a type of cancer that starts in the lymph nodes located inside the abdomen. It affects a specific type of white blood cell and typically requires chemotherapy or other cancer treatments. C83.13 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of lymphoid, hematopoietic and related tissue (c81-c96).
Under the CMS-HCC V28 risk adjustment model, C83.13 maps to Lung and Other Severe Cancers (HCC 20) with a community, non-dual, aged base RAF weight of 0.000. Under the older CMS-HCC V24 model, C83.13 maps to Lymphoma and Other Cancers (HCC 10) with a community, non-dual, aged base RAF weight of 0.675. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
Verify the anatomical site is specifically documented as intra-abdominal (within the abdomen) rather than other lymph node locations, as this affects the fifth character of the code. Because C83.13 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C83.13 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Verify the anatomical site is specifically documented as intra-abdominal (within the abdomen) rather than other lymph node locations, as this affects the fifth character of the code
- •Ensure the histology is confirmed as mantle cell lymphoma through pathology report; do not assume based on clinical suspicion alone
Clinical Significance
Mantle cell lymphoma of intra-abdominal lymph nodes is a common presentation given that mantle cell lymphoma frequently involves the gastrointestinal tract and associated lymph nodes. Abdominal involvement may cause pain, bowel obstruction, or masses detectable on imaging, and is typically identified during staging workup.
Documentation Requirements
- ✓Pathology-confirmed mantle cell lymphoma diagnosis
- ✓CT abdomen/pelvis or PET/CT documenting intra-abdominal lymph node involvement
- ✓Specific node groups identified (mesenteric, retroperitoneal, celiac, para-aortic)
- ✓Assessment for concurrent GI tract involvement (lymphomatoid polyposis)
- ✓Colonoscopy/endoscopy results if GI involvement is suspected